Evidence map›Paper›PMID 40568720›Full record

ArticleHaematologica2025

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.

Guillaume Moulis, Frederick Chen, Giuseppe Carli, Waleed Ghanima, Karolin Trautmann-Grill, Thomas Stauch, Alexandra Schifferli, Haroon Miah, Manuela Rueter, Lisanna Ghiotto and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Guillaume MoulisDepartment of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse, France; European Research Consortium on Immune thrombocytopenia (ERCI), founding member. moulis.g@chu-toulouse.fr.
Frederick ChenITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
Giuseppe CarliDepartment of Hematology, San Bortolo Hospital, Vicenza.
Waleed GhanimaEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Østfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
Karolin Trautmann-GrillMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden.
Thomas StauchUniversitätsklinikum Jena, Jena.
Alexandra SchifferliDepartment of Hematology/Oncology, University Children's Hospital Basel, Basel.
Haroon MiahITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
Manuela RueterDepartment of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse.
Lisanna GhiottoHematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.
Riccardo TomaselloØstfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
Annabell GeorgiMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden.
Vickie McDonaldGuy's Hospital, London.
Francesco ZajaEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; DSM, Università degli Studi di Trieste, Trieste.
Heidi Hassel PettersenØstfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
Thomas KühneEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Department of Hematology/Oncology, University Children's Hospital Basel, Basel.
Maria Luisa LozanoEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER, Murcia, Spain.
Tomás José González-LópezEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario de Burgos, Burgos, Spain.
Drew ProvanEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; ITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
Marc MichelEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Mondor University Hospital, Créteil.
Nichola CooperEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Imperial College London, London.
Francesco RodeghieroEuropean Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40568720
PMCPMC12666275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.